PT - JOURNAL ARTICLE AU - Jassat, Waasila AU - Mudara, Caroline AU - Vika, Caroline AU - Welch, Richard AU - Arendse, Tracy AU - Dryden, Murray AU - Blumberg, Lucille AU - Mayet, Natalie AU - Tempia, Stefano AU - Parker, Arifa AU - Nel, Jeremy AU - Perumal, Rubeshan AU - Groome, Michelle J. AU - Conradie, Francesca AU - Ndjeka, Norbert AU - Sigfrid, Louise AU - Merson, Laura AU - Cohen, Cheryl TI - A cohort study of Post COVID-19 Condition across the Beta, Delta and Omicron waves in South Africa: 6-month follow up of hospitalised and non-hospitalised participants AID - 10.1101/2022.10.31.22281748 DP - 2022 Jan 01 TA - medRxiv PG - 2022.10.31.22281748 4099 - http://medrxiv.org/content/early/2022/11/01/2022.10.31.22281748.short 4100 - http://medrxiv.org/content/early/2022/11/01/2022.10.31.22281748.full AB - Background A third of people may experience persistent symptoms following COVID-19. With over 90% of South Africans having evidence of prior SARS-CoV-2 infection, it is likely that many people could be affected by Post COVID-19 Condition (PCC).Methods The was a prospective, longitudinal observational cohort study recruiting hospitalised and non-hospitalised participants, infected during the periods that Beta, Delta and Omicron BA.1 variants dominated in South Africa. Participants aged 18 years or older were randomly selected to undergo telephone assessment at 1, 3 and 6 months after hospital discharge or laboratory-confirmed SARS-CoV-2 infection. Participants were assessed using a standardised questionnaire for evaluation of symptoms and health-related quality of life. We used negative binomial regression models to determine factors associated with the presence of ≥1 symptoms at 6 months.Findings Among hospitalised and non-hospitalised participants, 46.7% (1,227/2,626) and 18.5% (199/1,074) had ≥1 symptoms at 6 months (p=<0.001). Among hospitalised participants 59.5%, 61.2% and 18.5% experienced ≥1 symptoms at 6 months among individuals infected during the Beta, Delta and Omicron dominant waves respectively. Among PLWH who were hospitalised, 40.4% had ≥1 symptoms at 6 months compared to 47.1% among HIV-uninfected participants (p=0.108).Risk factors for PCC included older age, female sex, non-black race, the presence of a comorbidity, greater number of acute COVID-19 symptoms, hospitalisation/ COVID-19 severity and wave period (individuals infected during the Omicron-dominated wave had a lower risk of persistent symptoms [adjusted Incident Risk Ratio 0.45; 95% Confidence Interval 0.36 – 0.57] compared to those infected during the Beta-dominated wave). There were no associations between self-reported vaccination status before or after SARS-CoV-2 infection with persistent symptoms.Interpretation The study revealed a high prevalence of persistent symptoms among South African participants at 6 months although decreased risk for PCC among participants infected during the Omicron BA.1 wave. These findings have serious implications for countries with resource-constrained healthcare systems.Funding Bill & Melinda Gates Foundation, UK Foreign, Commonwealth & Development Office, and Wellcome.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was made possible by funding from the Bill & Melinda Gates Foundation (INV-008112 and INV-032725) and, through our collaboration with ISARIC, was supported by the UK Foreign, Commonwealth & Development Office, Wellcome (215091/Z/18/Z), and the Bill & Melinda Gates Foundation (OPP1209135).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the University of the Witwatersrand Human Research Ethics Committee (HREC M201150).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRestrictions apply to the availability of these data and so they are not publicly available. However, data can be made available from the corresponding author upon reasonable request and with the permission of the South African Department of Health and the NICD.